The PE Ratio as of September 2024 (TTM) for Prelude Therapeutics Incorporated (PRLD) is -2.74

According to Prelude Therapeutics Incorporated’s latest financial reports and current stock price. The company's current PE Ratio is -2.74. This represents a change of 24.07% compared to the average of -2.21 of the last 4 quarters.

Prelude Therapeutics Incorporated (PRLD) Historical PE Ratio (quarterly & annually)

How has PRLD PE Ratio performed in the past?

The mean historical PE Ratio of Prelude Therapeutics Incorporated over the last ten years is -25.53. The current -2.74 PE Ratio has changed 973.43% with respect to the historical average. Over the past ten years (40 quarters), PRLD's PE Ratio was at its highest in in the September 2023 quarter at -1.71. The PE Ratio was at its lowest in in the December 2020 quarter at -35.36.

Prelude Therapeutics Incorporated (PRLD) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Prelude Therapeutics Incorporated PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Prelude Therapeutics Incorporated (PRLD) Average PE Ratio

How has PRLD PE Ratio performed in the past?

The current PE Ratio of Prelude Therapeutics Incorporated (PRLD) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Prelude Therapeutics Incorporated (PRLD) PE Ratio vs. Peers

How is PRLD’s PE Ratio compared to its peers?

Prelude Therapeutics Incorporated’s PE Ratio is greater than Foghorn Therapeutics Inc. (-4.49), less than Shattuck Labs, Inc. (-2.08), greater than Monte Rosa Therapeutics, Inc. (-3.11), greater than Kymera Therapeutics, Inc. (-21.01), greater than Nurix Therapeutics, Inc. (-8.82), greater than C4 Therapeutics, Inc. (-3.44), greater than Eliem Therapeutics, Inc. (-3.49), greater than Cyteir Therapeutics, Inc. (-3.52), greater than Rezolute, Inc. (-3.80), less than Molecular Partners AG (-2.67), greater than Mineralys Therapeutics, Inc. (-4.63), less than AN2 Therapeutics, Inc. (-0.47), greater than Pharvaris N.V. (-8.20), greater than PepGen Inc. (-3.22), less than TCR2 Therapeutics Inc. (-0.44), greater than Revolution Medicines, Inc. (-13.31), greater than Black Diamond Therapeutics, Inc. (-3.70), less than Atreca, Inc. (-0.04), less than Passage Bio, Inc. (-0.57),

Build a custom stock screener for Prelude Therapeutics Incorporated (PRLD) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Prelude Therapeutics Incorporated using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Prelude Therapeutics Incorporated (PRLD) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Prelude Therapeutics Incorporated or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.